Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.
Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.
Across the July 2026 audit, compounded semaglutide spans about $79–$289 and tirzepatide $129–$349 per month. NexLife's flat $119/$139 (visits, shipping, labs included) is our pick for lowest predictable spend among fully transparent programs, though Embody is the cheaper raw sticker.
Watch the gap between the starter rate and the maintenance rate. Both drugs escalate over weeks, so tiered plans get more expensive at maintenance while a flat plan stays level (near $1,428/year at $119/month). Compare annualized cost at your effective dose, not the entry price.
Anchored in the data: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead 20.2% vs 13.7% in SURMOUNT-5, and a 20% MACE reduction for semaglutide in SELECT — with roughly two-thirds regain within a year of stopping.
This is comparison, not medical advice. Compounded GLP-1s are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and MTC/MEN2 contraindications.